1. Home
  2. DAN vs NAMS Comparison

DAN vs NAMS Comparison

Compare DAN & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dana Incorporated

DAN

Dana Incorporated

N/A

Current Price

$30.59

Market Cap

3.8B

ML Signal

N/A

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$23.32

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DAN
NAMS
Founded
1904
2019
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.1B
IPO Year
2003
2022

Fundamental Metrics

Financial Performance
Metric
DAN
NAMS
Price
$30.59
$23.32
Analyst Decision
Buy
Strong Buy
Analyst Count
5
8
Target Price
$40.60
$46.75
AVG Volume (30 Days)
1.3M
1.2M
Earning Date
04-29-2026
05-06-2026
Dividend Yield
1.34%
N/A
EPS Growth
264.10
32.81
EPS
9.93
N/A
Revenue
$7,500,000,000.00
$22,503,000.00
Revenue This Year
$1.89
$17.96
Revenue Next Year
$4.59
$540.65
P/E Ratio
$3.15
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.74
$23.05
52 Week High
$39.56
$42.21

Technical Indicators

Market Signals
Indicator
DAN
NAMS
Relative Strength Index (RSI) 53.29 28.37
Support Level $28.68 N/A
Resistance Level $31.83 $37.29
Average True Range (ATR) 0.91 1.16
MACD 0.00 -0.13
Stochastic Oscillator 47.99 0.19

Price Performance

Historical Comparison
DAN
NAMS

About DAN Dana Incorporated

Dana Inc is provider of products to virtually every vehicle manufacturer in the world. Its technologies include drive systems (axles, driveshafts and transmissions); electrodynamic technologies (motors, inverters, software and control systems, battery-management systems, and fuel cell plates); sealing solutions (gaskets, seals, cam covers, and oil pan modules); thermal-management technologies (transmission and engine oil cooling, battery and electronics cooling, charge air cooling, and thermal-acoustical protective shielding); and digital solutions (active and passive system controls and descriptive and predictive analytics). The company has two operating segments: Light Vehicle and Commercial Vehicle. The Light Vehicles segment generates the majority of revenue.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: